Triggering the extrinsic apoptotic pathway is an effective way to kill cutaneous T-cell lymphoma (CTCL) cells in vitro and ex vivo.
M ycosis fungoides and Sézary syndrome (SS) are 2 major forms of cutaneous T-cell lymphoma (CTCL). In this study, we use the term CTCL to refer specifically to mycosis fungoides and SS. On the basis of a variety of phenotypic, genetic, and functional investigations, there is ample evidence that CTCL is characterized by resistance to apoptosis. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] Often, CTCL cells express only low levels of extrinsic apoptotic pathway death receptors (DRs), such as Fas (CD95), and are less responsive to apoptotic triggers than are normal T cells. Activation-induced cell death (AICD) is a key pathway for apoptosis among CD4 + /CD45RO + memory T cells, the subset from which both mycosis fungoides (effector memory differentiation) and SS (central memory differentiation) are derived. Triggered through the T-cell receptor (TCR), AICD causes apoptosis through extrinsic (DR-mediated) pathways. It has been known for more than a decade that TCR signaling is defective in CTCL; however, the underlying mechanism was not apparent. 1, 5, [11] [12] [13] A previous study 14 found that the c-CBL E3 ubiquitin ligase is highly expressed in many cases of CTCL and that c-CBL knockdown using small interfering RNA technology restores the TCR signaling cascade that leads to upregulation of extrinsic pathway apoptosis in CTCL cells. We also found that some extrinsic apoptotic pathway factors, such as the Fas (CD95) DR, can be upregulated epigenetically by inhibition of promoter methylation using methotrexate or other folate analogues. 15 In aggregate, our findings provide proof of principle that by enhancing extrinsic pathway apoptosis CTCL cells can be killed effectively. Although c-CBL knockdown using small interfering RNA technology is an effective method for increasing CTCL apoptosis in vitro, it is not suitable for use in patients. Unfortunately, there are few other agents known to increase extrinsic apoptosis. Therefore, we performed a small molecule screen of more than 1700 compounds to search for those capable of inducing cleaved caspase 8 (a major indicator of extrinsic apoptosis). Nitrogen mustard (mechlorethamine, a US Food and Drug Administrationapproved topical therapy for CTCL) was among the highest generators of cleaved caspase 8. Gentian violet (GV; also known as crystal violet) was also identified as a compound that, when compared with nitrogen mustard, induced similar or greater levels of cleaved caspase 8 in CTCL cells without additional toxic effects on normal keratinocytes. Gentian violet is a triarylmethane dye that has been used for more than a century worldwide as an antimicrobial agent, cytologic stain, and the gram-positive stain for classifying bacteria. 16, 17 In this study, we used in vitro and ex vivo models to analyze the association of this ubiquitous, inexpensive compound with activation of extrinsic pathway apoptosis that involves the Fas and tumor necrosis factor (TNF)-related apoptosisinducing ligand (TRAIL) DRs and levels of nuclear factor (NF)-κB components that are typically overexpressed in advanced-stage CTCL and drive tumor cell proliferation.
Methods

CTCL Cell Lines and SS Blood Cells
Human CTCL cell lines MyLa, HH, SZ4, Hut-78, and SeAx and their culture conditions were described previously. 6, 15 The acute T-cell lymphoblastic leukemia cell line Jurkat was obtained from the American Type Culture Collection. It was included in some studies for comparative purposes. Blood samples from patients with SS samples were obtained. The mononuclear cells were separated from the whole blood and cultured in the same conditions as the SZ4 cell line. Most cells were assessed to be tumor cells as described previously. 8 Cells were treated with GV (Sigma-Aldrich) or dimethyl sulfoxide (DMSO) diluted to final concentrations of 1 to 100 μmol/L in culture medium. In some experiments, cells were treated with methotrexate (MP Biomedicals) dissolved in DMSO and diluted to 10 μmol/L in culture medium. This study was approved by the institutional review board of University of Wisconsin, Madison, and all patients provided written informed consent. All data were deidentified.
High-Throughput Screening
We used the Small Molecule Screening Facility at the University of Wisconsin Comprehensive Cancer Center to identify small molecules that induce extrinsic apoptosis in CTCL. We used the HH CTCL cell line in an enzyme-linked immunosorbent assay to quantitatively detect the level of cleaved caspase 8 induced by 1710 unique compounds contained in the National Institutes of Health Clinical Collection, Selleck Kinase Inhibitor Library, and Prestwick Chemical Library.
Flow Cytometry
Percentage of apoptotic cells; levels of cleaved caspases (8, 9, 3, and 2); expression of Fas, Fas ligand (FasL), DR4, DR5, TRAIL, TNF receptor 1 (TNF-R1), and TNF-α; and levels of phosphorylated phospholipase C-γ1 (PLC-γ1), calcium mobilization, and reactive oxygen species (ROS) were assessed by flow cytometry and analyzed as described previously. 18 Phycoerythrinconjugated anticleaved caspases (8, 9, 3, and 2), anti-DR4 (TRAIL-R1), anti-DR5 (TRAIL-R2), and anti-TRAIL were obtained from PD Biosciences. Anti-TNF-R1 primary antibody was obtained from Santa Cruz Biotechnology, and fluorescein isothiocyanate conjugated anti-TNF-α was obtained from Molecular Probes. Secondary antibodies were described previously. 18 For analysis of apoptosis, the total numbers of both annexin V single-positive cells (early apoptosis) and annexin V and propidium iodide double-positive cells (late apoptosis) were interpreted as apoptotic cells.
Key Points
Question Are there cost-effective alternatives to therapies currently available for early-stage cutaneous T-cell lymphoma?
Findings Using in vitro and ex vivo methods, this study performed high-throughput screening of 1710 compounds and identified gentian violet as an anti-cutaneous T-cell lymphoma agent that induces high levels of tumor cell death and blocks tumor cell growth.
Meaning These preclinical data suggest that gentian violet (a well-known topical antimicrobial agent) has potential as a novel topical therapy for cutaneous T-cell lymphoma that is inexpensive and available worldwide.
Western Blotting
Western blotting was performed as described previously. 18 Anticleaved caspases 8, 9, and 3, anti-myeloid cell leukemia 1 (MCL-1), anti-NF-κB1, anti-RelA, anti-NF-κB2, and anti-RelB primary antibodies were obtained from Cell Signaling. Horseradish peroxidase-conjugated appropriate secondary antibodies and loading control anti-β-actin antibody were obtained from Cell Signaling. The blots were analyzed as described previously. 18 
Statistical Analysis
Statistical analysis was performed using the 2-tailed, paired t test and analysis of variance. A 2-sided P < .05 was considered to be statistically significant.
Results
GV as a CTCL Killer
Among the 1710 unique compounds screened, nitrogen mustard proved to be among the best inducers of cleaved caspase 8; however, GV was identified as another compound of interest that also induced high levels of cleaved caspase 8 in the HH CTCL cell line.
Apoptosis in CTCL Cell Lines and SS Blood Samples
In vitro experiments of annexin V flow cytometry demonstrated that GV (1 μmol/L) induced 40% to 70% apoptosis at 24 hours among 5 CTCL lines ( Figure 1A ). Gentian violet is also associated with the T-cell acute lymphoblastic leukemia line Jurkat, which was included for comparison. Ex vivo experiments showed even greater apoptosis of 75% to 90% for GV among SS blood samples. In some cases, apoptosis was significantly greater than that observed using nitrogen mustard at the same concentration. Apoptosis of normal keratinocytes was less than that of nitrogen mustard, consistent with the clinical observation that GV is well tolerated as a topical agent. As shown by dose titration experiments in Figure 1B , at 24 hours, significant apoptosis was induced by GV at 1 μmol/L, and apoptosis did not increase much beyond the 50-μmol/L concentration.
Extrinsic and Intrinsic Apoptotic Pathways
As shown in Figure 2 , we examined changes in the activation of various caspases in response to GV. Cleavage of caspase 8 and caspase 9 is indicative of extrinsic (DR) and intrinsic (mitochondrial) apoptotic pathways, respectively. Caspase 2 involves an alternative upstream pathway, and cleavage of caspase 3 is a downstream indicator of total apoptosis. Among CTCL cell lines, GV primarily induced extrinsic pathway activation (cleaved caspase 8), whereas SS blood cells showed activation of the extrinsic and intrinsic pathways. Caspase 2 was not affected. In some instances, the GV-induced findings were significantly greater than those of nitrogen mustard. These flow cytometric alterations were confirmed by immunoblot analy- sis as shown in eFigure 1 in the Supplement, which also shows that the antiapoptotic factor MCL-1 was reduced by GV in CTCL lines and SS blood cells.
FasL, TRAIL Pathway Factors, and FasL-Related Signaling Components
Because of the prominent augmentation of extrinsic pathway activity, we examined alterations of the Fas, TRAIL, and TNF apoptotic subpathways. As shown in Figure 3 and eFigure 2 and eFigure 3 in the Supplement, GV induced significant up-regulation of FasL and all 3 TRAIL components (TRAIL, DR4, and DR5) but not Fas or any TNF components. This finding suggests that GV-mediated extrinsic pathway apoptotic activity was dependent on the Fas and TRAIL subpathways. Furthermore, triggering of AICD requires a TCR signal transduction pathway that involves phosphorylation of PLC-γ1 followed by calcium flux and generation of ROS. As shown in Figure 3 and eFigure 3 in the Supplement, all these factors were enhanced by GV. In addition, in many instances, the enhancement was significantly greater than that of nitrogen mustard throughout this series of experiments.
NF-κB Expression and CTCL Cell Proliferation
NF-κB is a known proliferative driver of CTCL, and overexpression of NF-κB components is a common feature of CTCL. [19] [20] [21] [22] [23] [24] As shown in eFigure 4 in the Supplement, immunoblot analysis demonstrated that canonical (NF-κB/RelA) and alternative (NF-κB2/RelB) NF-κB components were reduced by GV in CTCL lines and SS blood samples. Subsequent experiments showed that GV modestly increased inhibitory κB (IκB), a factor that inhibits NF-κB subunits. Furthermore, as shown in Figure 4 , these changes were associated with decreased CTCL cell proliferation and cell cycle shifts with G2/S phase arrest.
Association of GV-Induced Apoptosis and Methotrexate
A prior study 15 found that methotrexate enhances CTCL apoptosis in part by derepressing expression of the Fas DR by inhibiting methylation of its promoter. Because GV upregulated FasL, we theorized that the upregulation of its receptor Fas by methotrexate would be associated with even greater induction of apoptosis than would GV alone. As shown in Figure 5 , combination GV and methotrexate treatment induced 70% to 90% apoptosis at 24 hours in CTCL lines and SS blood cells. This level of apoptosis was significantly greater than that observed with GV or methotrexate alone. The key role of Fas and FasL in this increased apoptosis was supported by the lack of enhanced apoptosis observed in the SeAx CTCL cell line. SeAx is known to be Fas null 7 and therefore unable to respond to the Fasenhancing activity of methotrexate.
Discussion
In addition to its role as an antifungal and antibacterial agent, GV has anticancer properties. [25] [26] [27] [28] [29] [30] Prior work 27, [31] [32] [33] has found that GV inhibits nicotimamide adenine dinucleotide phosphate oxidases, NF-κB, and ANG-2 while inducing p53 and IκB in various cell types. Our current findings add to this knowledge base by detailing the association between GV and CTCL cells. We used in vitro and ex vivo approaches to show that GV induced major levels of apoptosis in CTCL lines and SS blood cells. As shown in Figure 1 , Figure 2 , and Figure 3 and eFigure 1 and eFigure 2 in the Supplement, the apoptosis involved mainly the extrinsic pathway in some cases and both the extrinsic and intrinsic pathways in others. Extrinsic apoptosis occurs largely via the Fas and TRAIL subpathways, whereas intrinsic apoptosis is associated with reduction in antiapoptotic factors, such as MCL-1. As shown in Figure 4 and eFigure 4 in the Supplement, while GV augments apoptosis, it diminishes CTCL proliferative drivers, such as NF-κB components, and enhances expression of IκB. This finding is associated with cell cycle arrest and reduced CTCL tumor cell proliferation, which simultaneously attack CTCL viability and growth. As shown in Figure 5 , the increase in GV-induced apoptosis in CTCL was greater when GV was combined with methotrexate. A previous study 3 found that in addition to its role as an S-phase inhibitor that blocks purine synthesis, methotrexate has novel activity as a DNA methylation inhibitor by blocking synthesis of S-adenosylmethionine, the principal methyl donor for DNA methyltransferases. Therefore, methotrexate inhibits cell proliferation through the cell cycle and enhances apoptosis through epigenetic derepression of Fas, FasL, and other apoptotic factors by inhibiting promoter methylation. The specific role of Fas derepression is underscored by the inability of methotrexate to enhance SeAx apoptosis. This CTCL line is Fas null and therefore unable to upregulate Fas in response to methotrexate. 7 The TCR is expressed on the cell surface in association with CD3 proteins to form the TCR/CD3 complex. During AICD, engagement of TCR/CD3 normally leads to activation of proximate tyrosine kinases, such as Zap70, and a subsequent downstream cascade that involves phosphorylation of PLC-γ1, calcium mobilization, generation of ROS, and FasL upregulation. 5, 11, 34 As shown in Figure 3 and eFigure 3 in the Supplement, the ability of GV to enhance extrinsic apoptosis via the AICD mechanism is supported by the concomitant increases in phosphorylated PLC-γ1, calcium flux, ROS generation, and FasL observed in this study.
Limitations
The limitations of this study include analysis restricted to CTCL cell lines and blood samples from patients with SS. These are both advanced forms of CTCL and do not necessarily predict the response of early CTCL tumor cells to GV. In addition, the results reported here are preclinical findings based on in vitro and ex vivo experiments. Therefore, they cannot predict the actual efficacy or toxic effects of GV in the clinical setting.
Conclusions
Despite extensive analysis, no uniform targetable mutation has been discovered to date that accounts for the pathogenesis of CTCL. 13 Therefore, our research has focused on interventions that enhance CTCL apoptosis and impede tumor cell proliferation. Our current findings indicate that GV has these important characteristics. Used throughout the world for more than a century as an antimicrobial agent and tissue dye, it is well tolerated topically on the skin and oral mucosa. 32 Our preclinical data suggest that GV might be an effective topical agent for early-stage CTCL. Although purple at a neutral pH, GV is rendered colorless or nearly so when the pH is adjusted in either direction. The well-established antimicrobial actions of GV would be advantageous for the dermatophyte and bacterial infections that sometimes complicate the treatment of patients with CTCL. [35] [36] [37] In particular, staphylococcal infections can be problematic in patients with CTCL and have been implicated in exacerbating the severity of CTCL. 35, 36 There is also a social justice aspect to GV. In an era of high-priced anticancer drugs that are inaccessible to many patients throughout the world, GV (like methotrexate) is an inexpensive compound that is widely available. Physicians around the globe are familiar with its use. Clinical studies will be needed to determine the efficacy of topical GV therapy for early-stage CTCL; however, our preclinical data provide justification for further investigations. Role of the Funder/Sponsor: The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. 
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